Clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in China: A nationwide cross-sectional study

Study identification

• EU PAS number:
  EUPAS17922
• Study ID:
  17923
• Official title and acronym:
  Clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in China: A nationwide cross-sectional study
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  Clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in China: A nationwide cross-sectional study
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned:16/11/2015

Actual:16/11/2015

Study start date

Planned:15/03/2017

Actual:09/03/2017

Data analysis start date

Planned:15/03/2017

Date of final study report

Planned:04/09/2018

Actual:02/08/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

1218.174